BioGaia AB is a biotechnology company based in Stockholm, Sweden, specializing in probiotics. The company is recognized as a leading entity in the development of probiotic products aimed at enhancing gut, immune, and oral health. BioGaia has a strong focus on innovative research, which has led to the granting of patents for its unique probiotic formulations. This commitment to research and development has resulted in an extensive portfolio of published studies concerning various bacterial strains.
The company's products are available in multiple countries, reflecting its global reach and impact in the health and wellness sector. BioGaia's long history of research and innovation underscores its dedication to advancing knowledge and applications in probiotic science. Additionally, the company provides resources for stakeholders, including investor presentations and financial reports, as well as earnings call replays, which facilitate transparency and communication with its investors.